The winners of the 2018 PharmaTimes Clinical Researcher of the Year competition were announced at an awards ceremony and gala dinner last night. It followed a day of fierce competition at the Regency Hyatt, in which 55 individual finalists and
read moreBiogen CEO Michel Vounatsos totted up a healthy $13.6 million in the usual mix of pay, shares and other compensation last year, but he’ll likely need some big R&D deals and wins to boost the company’s outlook—and lift his pay
read moreGlaxoSmithKline’s Shingrix carried high expectations, but it turns out that those ambitious projections weren’t high enough. In the first quarter, the shingles vaccine generated £110 million, nearly triple analyst estimates of £40 million. And the revenue couldn’t come at a better time for GSK. More:
read moreJust months after completing China’s largest single use bioreactor manufacturing facility, WuXi Biologics is ready to take its technology to Europe with another large biologics facility that will employ 400 workers. More: China's WuXi Biologics to build biologics plant in Ireland that
read moreAllergan may be facing investor pressure to sell off some businesses—and to get its share price back on an upward trajectory—but the company managed to beat Street estimates with its first-quarter earnings. And that’s despite generic competition for some of
read moreThat was remarkably fast: Just nine days into its Gardasil 9 review, China’s revamped drug regulator handed Merck’s HPV vaccine a conditional green light—a new approval tool the agency is testing in its quest to speed new drugs to market.
read more© 1994 - 2025 B.M. Pharmaceuticals